Compositions and methods relating to proliferative diseases

Patent metadata

Field	Value
Publication number	US-9556101-B2
Application number	US-201414328062-A
Country	US
Kind code	B2
Filing date	Jul 10, 2014
Priority date	Dec 6, 2010
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.

First claim

The invention claimed is:

1. An anti-cancer pharmaceutical composition, comprising:
N-methylabietylamine/GPR-7 {[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}(methyl)amine; and a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises liposomes.

3. A method of treating a subject having cancer, comprising: administering a therapeutically effective amount of the anti-cancer pharmaceutical composition of claim 1 to the subject.

4. The method of claim 3 , wherein the anti-cancer pharmaceutical composition is effective to preferentially inhibit the PI3K, MAPK and STAT pathways in a cancer cell compared to a non-cancer cell.

5. The method of claim 3 , wherein the subject is human.

6. The method of claim 3 , further comprising administration of an adjunct anti-cancer treatment.

Assignees

• Penn State Res Found

Inventors

• Robertson Gavin P
• Chandagalu D Raghavendra Gowda
• Madhunapantula Subbarao V
• Inamdar Gajanan S
• Kuzu Omer F

Classifications

• A61K31/215

  of carboxylic acids · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/135 Primary

  having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title

• A61K31/155

  Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title